Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.66 |
| ▸ | CTSL | P07711 | 1/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.57 |
| ▸ | NMT2 | O60551 | 2/20 | 0.54 |
| ▸ | NMT1 | P30419 | 2/20 | 0.54 |
| ▸ | FURIN | P09958 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445569 | 1.00 | SLC6A5 (0.66) | SLC6A5CTSLNOD1NMT2NMT1 | |
| Acetic Acid SCHEMBL25220206 | 0.98 | SLC6A5 (0.64) | SLC6A5CTSLNOD1NMT2NMT1 | |
| Acetic Acid SCHEMBL30391850 | 0.98 | SLC6A5 (0.64) | SLC6A5CTSLNOD1NMT2NMT1 | |
| SCHEMBL29520919 | 0.98 | SLC6A5 (0.64) | SLC6A5CTSLNOD1NMT2NMT1 | |
| SCHEMBL30496969 | 0.95 | SLC6A5 (0.68) | SLC6A5CTSLNOD1NMT2NMT1 | |
| SCHEMBL29640336 | 0.95 | SLC6A5 (0.68) | SLC6A5CTSLNOD1NMT2NMT1 | |
| SCHEMBL29640314 | 0.95 | SLC6A5 (0.68) | SLC6A5CTSLNOD1NMT2NMT1 | |
| SCHEMBL30496949 | 0.95 | SLC6A5 (0.68) | SLC6A5CTSLNOD1NMT2NMT1 | |
| SCHEMBL13811916 | 0.95 | SLC6A5 (0.59) | SLC6A5CTSLNOD1NMT2NMT1 | |
| Trifluoroacetic Acid SCHEMBL3500386 | 0.94 | SLC6A5 (0.59) | SLC6A5CTSLNOD1NMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626904-A1 | MANDELIC ACID SALT OF PALMITOYL LYSYLVALYL-LYSINE | DSM IP Assets B.V. (NL) | 2025-10-08 | — | — | EP | claimed |
| EP-4316460-B1 | COSMETIC COMPOSITIONS COMPRISING A SYNERGIC MIX OF ACTIVE INGREDIENTS HAVING ANTIAGING ACTIVITY | UNIFARCO S P A (IT) | 2025-09-03 | — | — | EP | claimed |
| EP-4501342-A1 | COMPOSITION WITH ANTIVIRAL, ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY | Elysium Cell Bio Ita Srl (IT) | 2025-02-05 | — | — | EP | claimed |
| WO-2024115619-A1 | MANDELIC ACID SALT OF PALMITOYL LYSYLVALYL-LYSINE | DSM IP ASSETS B.V. (NL) | 2024-06-06 | — | — | WO | claimed |
| US-20240139292-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSITIVE SKIN | PURE VITALITY INC (US) | 2024-05-02 | — | — | US | claimed |
| WO-2024027193-A1 | SKIN-CARE PRODUCT COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SULFONATED CALIXARENE, AND USE OF SULFONATED CALIXARENE | 苏州隽德生物科技有限公司 | 2024-02-08 | — | — | WO | claimed |
| EP-4151202-A1 | COMPOSITION FOR PREVENTING AND/OR TREATING WHITE STRETCH MARKS | LSI Silderma Ltd (IE) | 2023-03-22 | — | — | EP | claimed |
| WO-2022192050-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSITIVE SKIN | PURE VITALITY, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| US-20120064020-A1 | NOVEL COMPOSITION | DSM IP ASSETS B.V. (NL) | 2012-03-15 | — | — | US | claimed |
| CN-102325543-A | Compositions comprising N2- (1-oxohexadecyl) -lysyl-valyl-lysine for the treatment of rosacea and symptoms thereof | DSM IP ASSETS BV | 2012-01-18 | — | — | CN | claimed |
| EP-2398489-A2 | COMPOSITION COMPRISING N2 - (1-OXOHEXADECYL) - LYSYL - VALYL - LYSINE FOR TREATING ROSACEA AND ITS SYMPTOMS | DSM IP Assets B.V. (NL) | 2011-12-28 | — | — | EP | claimed |
| US-20110086060-A1 | NOVEL COMPOSITIONS AND THEIR USE | DSM IP ASSETS B.V. (NL) | 2011-04-14 | — | — | US | claimed |
| WO-2010094452-A2 | NOVEL COMPOSITION | DSM IP ASSETS B.V. (NL) | 2010-08-26 | — | — | WO | claimed |
| WO-2009124971-A2 | NOVEL COMPOSITIONS AND THEIR USE | DSM IP ASSETS B.V. (NL) | 2009-10-15 | — | — | WO | claimed |
| CN-122056799-A | Sensitive muscle barrier repair composition and preparation method and application thereof | 青岛中科蓝智生物科技发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115118-A1 | COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK | SEEVIX MATERIAL SCIENCES LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| US-12453688-B2 | Cosmetic compositions comprising dragline spider silk | SEEVIX MATERIAL SCIENCES LTD. (IL) | 2025-10-28 | — | — | US | disclosed |
| WO-2009124971-A2 | NOVEL COMPOSITIONS AND THEIR USE | DSM IP ASSETS B.V. (NL) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008136676-A2 | COSMETIC ANTI-AGEING SKIN CARE COMPOSITIONS | TUPPERWARE PRODUCTS S.A (CH) | 2008-11-13 | — | — | WO | disclosed |
| EP-1790330-A2 | Cosmetic and dermatological compositions containing oligopeptides and apple extract | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115118-A1 | COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK | CUTA, MC1R, SPPL2B | SLC6A5 3995/4885CTSL 1979/4885NOD1 4116/4885 |
| US-12453688-B2 | Cosmetic compositions comprising dragline spider silk | MSH6, TYR, PDE7B | SLC6A5 4216/4885CTSL 4681/4885NOD1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.